<DOC>
	<DOCNO>NCT00978549</DOCNO>
	<brief_summary>RATIONALE : Analgesics , antiemetic , steroid , radiation therapy effective help control symptom cause cancer . It yet know whether treatment effective give without docetaxel treat patient relapsed esophageal cancer stomach cancer . PURPOSE : This randomized phase II trial study symptom control give together docetaxel see well work compare symptom control give without docetaxel treat patient relapsed esophageal cancer stomach cancer .</brief_summary>
	<brief_title>Symptom Control With Without Docetaxel Treating Patients With Relapsed Esophageal Cancer Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare overall survival patient relapse adenocarcinoma esophagus stomach treatment docetaxel active symptom control v active symptom control alone . Secondary - To determine time documented progression patient treat docetaxel . - To assess response rate docetaxel patient treat docetaxel . - To determine toxicity docetaxel patient treat docetaxel . - To assess quality life patient . - To evaluate health economic impact . OUTLINE : This multicenter study . Patients stratify accord stage ( locally advance vs metastatic ) , site disease ( esophagus v esophagogastric junction v stomach ) , duration response prior chemotherapy ( response v response duration &lt; 3 month vs response duration 3-6 month ) , ECOG performance status ( 0-1 v 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 active symptom control ( e.g. , analgesic [ include opioids ] , antiemetic , steroid , palliative radiotherapy ) daily . - Arm II : Patients receive active symptom control arm I . Courses repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients arm I undergo tissue biopsy collection baseline 3 course treatment biomarker analysis . Quality life assess QLQ-C30 QLQ-STO22 questionnaire baseline 3 , 6 , 9 , 12 , 18 , 24 week . Health resource use assess EQ-5D questionnaire baseline periodically treatment . After completion study treatment , patient follow every 6 week 1 year every 3 month thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma esophagus stomach , include adenocarcinoma esophagogastric junction Advanced disease amenable curative treatment Documented progressive disease receive within 6 month completion firstline chemotherapy platinum fluoropyrimidinebased therapy either advance disease neoadjuvant/perioperative therapy No cerebral leptomeningeal metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Hemoglobin ≥ 10 g/dL WBC ≥ 3.0 x 10^9/L ANC ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Creatinine normal OR creatinine clearance ≥ 60 mL/min Total bilirubin normal ALT ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion treatment No clinically significant peripheral neuropathy ( grade 24 ) No prior malignancy except curatively treat basal cell carcinoma skin cervical intraepithelial neoplasia No medical psychiatric condition would influence ability patient provide inform consent No serious uncontrolled illness , opinion investigator , make undesirable patient enter trial PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy taxanes ≤ 1 prior chemotherapy regimen advance setting allowed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>pain</keyword>
	<keyword>nausea vomit</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IIIA gastric cancer</keyword>
	<keyword>stage IIIB gastric cancer</keyword>
	<keyword>stage IIIC gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>